JP2004517808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517808A5 JP2004517808A5 JP2002513464A JP2002513464A JP2004517808A5 JP 2004517808 A5 JP2004517808 A5 JP 2004517808A5 JP 2002513464 A JP2002513464 A JP 2002513464A JP 2002513464 A JP2002513464 A JP 2002513464A JP 2004517808 A5 JP2004517808 A5 JP 2004517808A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- pharmaceutical composition
- substituted
- benzyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 31
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 16
- 229940125717 barbiturate Drugs 0.000 description 13
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 230000004112 neuroprotection Effects 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 230000001624 sedative effect Effects 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- IKVPZYAOGOJTLK-UHFFFAOYSA-N 5,5-diphenyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1NC(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 IKVPZYAOGOJTLK-UHFFFAOYSA-N 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 5
- RRFBTKHQZRCRSS-UHFFFAOYSA-N 1,3-bis(methoxymethyl)-5,5-diphenyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COC)C(=O)N(COC)C(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 RRFBTKHQZRCRSS-UHFFFAOYSA-N 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- SQCVEQVZGPHNTJ-UHFFFAOYSA-N 1-(methoxymethyl)-5,5-diphenyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(COC)C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 SQCVEQVZGPHNTJ-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 0 *C(*)(C(N(*)C(N1*)=O)=O)C1=O Chemical compound *C(*)(C(N(*)C(N1*)=O)=O)C1=O 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22167200P | 2000-07-26 | 2000-07-26 | |
| US60/221,672 | 2000-07-26 | ||
| PCT/US2001/023420 WO2002007729A1 (en) | 2000-07-26 | 2001-07-26 | Non-sedating barbiturate compounds as neuroprotective agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517808A JP2004517808A (ja) | 2004-06-17 |
| JP2004517808A5 true JP2004517808A5 (enExample) | 2008-09-11 |
| JP5047442B2 JP5047442B2 (ja) | 2012-10-10 |
Family
ID=22828824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002513464A Expired - Fee Related JP5047442B2 (ja) | 2000-07-26 | 2001-07-26 | 神経保護剤としての非鎮静バルビツレート化合物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1311270B1 (enExample) |
| JP (1) | JP5047442B2 (enExample) |
| CN (2) | CN100522172C (enExample) |
| AT (1) | ATE383159T1 (enExample) |
| AU (2) | AU8077801A (enExample) |
| BR (1) | BR0112775A (enExample) |
| CA (1) | CA2416535C (enExample) |
| DE (1) | DE60132337T2 (enExample) |
| ES (1) | ES2300349T3 (enExample) |
| IL (3) | IL154060A0 (enExample) |
| MX (1) | MXPA03000824A (enExample) |
| PT (1) | PT1311270E (enExample) |
| WO (1) | WO2002007729A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
| US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| EP1311270B1 (en) * | 2000-07-26 | 2008-01-09 | Taro Pharmaceutical Industries Limited | Non-sedating barbiturate compounds as neuroprotective agents |
| US6939873B2 (en) | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| CN1896084A (zh) * | 2002-01-30 | 2007-01-17 | 塔罗制药工业有限公司 | 非镇静性巴比土酸衍生物 |
| CN102283821A (zh) * | 2002-10-11 | 2011-12-21 | 巴克斯特国际公司 | 含有卤化挥发性麻醉药的制剂在制备通过肠外给药用于治疗组织具有缺血事件的患者的制剂中的应用 |
| CN100502871C (zh) * | 2002-12-11 | 2009-06-24 | 塔罗制药工业有限公司 | 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用 |
| EP1625848A1 (en) * | 2004-08-10 | 2006-02-15 | Taro Pharmaceuticals North America, Inc. | Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| RU2370266C2 (ru) * | 2007-12-21 | 2009-10-20 | Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" | Способ общего обезболивания |
| WO2013038427A1 (en) * | 2011-09-12 | 2013-03-21 | Council Of Scientific & Industrial Research | ARYLATED β-DICARBOIMYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF |
| CN102863579B (zh) * | 2012-09-14 | 2014-02-05 | 东南大学 | 一种巴比妥酸螯合树脂及其制备方法和应用 |
| CN113640512B (zh) | 2015-10-05 | 2024-12-31 | 北卡罗来纳-查佩尔山大学 | 用于多路测定的解码方法及相关流体设备、试剂盒和固体支持物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL69722A (en) * | 1983-09-14 | 1986-09-30 | Taro Pharma Ind | Oxopyrimidine derivatives and pharmaceutical compositions containing them |
| US4833148A (en) * | 1987-04-09 | 1989-05-23 | Washington University | Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| EP1311270B1 (en) * | 2000-07-26 | 2008-01-09 | Taro Pharmaceutical Industries Limited | Non-sedating barbiturate compounds as neuroprotective agents |
-
2001
- 2001-07-26 EP EP01959195A patent/EP1311270B1/en not_active Expired - Lifetime
- 2001-07-26 AT AT01959195T patent/ATE383159T1/de not_active IP Right Cessation
- 2001-07-26 WO PCT/US2001/023420 patent/WO2002007729A1/en not_active Ceased
- 2001-07-26 PT PT01959195T patent/PT1311270E/pt unknown
- 2001-07-26 JP JP2002513464A patent/JP5047442B2/ja not_active Expired - Fee Related
- 2001-07-26 AU AU8077801A patent/AU8077801A/xx active Pending
- 2001-07-26 IL IL15406001A patent/IL154060A0/xx unknown
- 2001-07-26 CA CA2416535A patent/CA2416535C/en not_active Expired - Fee Related
- 2001-07-26 CN CNB2006100813267A patent/CN100522172C/zh not_active Expired - Fee Related
- 2001-07-26 ES ES01959195T patent/ES2300349T3/es not_active Expired - Lifetime
- 2001-07-26 MX MXPA03000824A patent/MXPA03000824A/es active IP Right Grant
- 2001-07-26 BR BR0112775-6A patent/BR0112775A/pt not_active Application Discontinuation
- 2001-07-26 DE DE60132337T patent/DE60132337T2/de not_active Expired - Lifetime
- 2001-07-26 CN CNB018151426A patent/CN1329032C/zh not_active Expired - Fee Related
- 2001-07-26 AU AU2001280778A patent/AU2001280778B2/en not_active Ceased
-
2003
- 2003-01-20 IL IL154060A patent/IL154060A/en not_active IP Right Cessation
-
2004
- 2004-11-03 IL IL16501704A patent/IL165017A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| ES2257757T3 (es) | Carboxilato de terfenadina y el tratamiento de trastornos alergicos. | |
| CA2404152C (en) | Inhibition of cyclooxygenase-2 activity | |
| JP2004517808A5 (enExample) | ||
| ES2242398T3 (es) | Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio. | |
| JP2003509349A5 (enExample) | ||
| JP2005515966A5 (enExample) | ||
| CZ254196A3 (en) | PHARMACEUTICAL PREPARATION AND USE OF TRANS-5-CHLORO-2-METHYL-2,3,3a,12b-TETRAHYDRO-1H-DIBENZ£2,3:6,7|OXEPINO £4,5-c|PYRROLE FOR PREPARING THE PHARMACEUTICAL PREPARATION | |
| JP2002519425A5 (enExample) | ||
| JP2002537258A5 (enExample) | ||
| AU679910B2 (en) | Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient | |
| HU211666A9 (en) | Antiviral compounds | |
| CA2416535A1 (en) | Non-sedating barbiturate compounds as neuroprotective agents | |
| JP2006510606A5 (enExample) | ||
| PT93654A (pt) | Processo para a preparacao de composicoes farmaceuticas sinergicas contendo 3-{2-{4-(4-fluoro-benzoil)-1-piperidinil}etil}-2,4-(1h,3h)-quinazolina-diona (ketanserina) | |
| JP2007527904A5 (enExample) | ||
| JP2010533166A (ja) | シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤 | |
| CA2476825A1 (en) | Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases | |
| AU4303400A (en) | Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders | |
| US5049568A (en) | Liquid pharmaceutical composition for piperidinoalkanol derivatives | |
| JPH03215426A (ja) | 血糖上昇抑制剤 | |
| WO2001041535A3 (en) | Eplerenone crystalline form | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| HUP0203790A2 (hu) | (6-Metoxi-2-naftil)-ecetsav prodrugokat tartalmazó gyógyszerkészítmények alkalmazása gyulladás kezelésére | |
| EP0968715B1 (en) | Loratadine for use as an antiarrhymthmic |